Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Current Status, Challenges and Future of Precision Medicine for Colorectal...
share announcement

Current Status, Challenges and Future of Precision Medicine for Colorectal Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 1 October 2024 | Viewed by 763

Special Issue Editors

Prof. Dr. Brian Davidson

E-Mail Website
Guest Editor
Division of Surgery & Interventional Sciences, University College London, London, UK
Interests: pathogenesis of HPB cancers; surgical innovation; organ preservation; machine perfusion; US histotripsy; irreversible electroporation (IRE); evidence based healthcare
Prof. Dr. Jamie Murphy

E-Mail Website
Guest Editor
Department of Surgery and Cancer, Imperial College London, London, UK
Interests: innovations in management of stage 4 colorectal cancer; locally advanced colorectal cancer; recurrent rectal cancer; peritoneal cancer; anal cancer
Dr. Khurum Khan

E-Mail Website
Guest Editor
Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, 235 Euston Road, London NW1 2BU, UK
Interests: colorectal cancer; anal cancer; bile duct cancer (cholangiocarcinoma); biliary cancer; cancer of unknown primary; colon cancer; gastrointestinal cancers; medical oncology; small bowel cancer liquid biopsies; tumour heterogeneity; patient-derived organoids; bioinformatics; next generation sequencing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Precision medicine or personalized medicine is a rapidly evolving approach in colorectal cancer treatment in which therapy is tailored to individual patients based on the integration of data onthe disease characteristics on imaging, the histological phenotype of the cancer, the cancer genomic and proteomic profiles, the natural history of the disease progression and the response patterns to treatment. Increasingly this complex integration of information is used to anticipate treatment responses and the optimization of therapy.

This special issue aims to provide a comprehensive overview of the current status, challenges, and future prospects of precision medicine in colorectal cancer. It explores the molecular classification of colorectal cancer and highlights the recent advancements in targeted therapies, immunotherapies, and liquid biopsies. The impact of this molecular information and immunological treatment on surgical management of primary and metastatic disease will be reviewed including controversial areas such as synchronous bowel and liver resection and liver transplant for colorectal cancer.

We will explore the potential of next-generation sequencing, radiomics, artificial intelligence and machine learning to improve the diagnosis, prognosis and monitoring of CRC patients. We hope that this special issue will provide a comprehensive and updated overview of precision medicine for CRC and stimulate further research and innovation in this field. We look forward to receiving your contributions.

Prof. Dr. Brian Davidson
Prof. Dr. Jamie Murphy
Dr. Khurum Khan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer 
  • precision medicine
  • personalised medicine
  • synchronous resection 
  • downstaging 
  • liver transplant 
  • molecular profiling 
  • biomarkers 
  • radiomics 
  • targeted therapy 
  • immunotherapy 
  • liquid biopsy 
  • next-generation sequencing 
  • machine learning 
  • artificial intelligence

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

26 pages, 762 KiB  
Review
Challenges and Opportunities for Precision Surgery for Colorectal Liver Metastases
by Robert Michael O’Connell and Emir Hoti
Cancers 2024, 16(13), 2379; https://doi.org/10.3390/cancers16132379 - 28 Jun 2024
Viewed by 533
Abstract
The incidence of colorectal cancer and colorectal liver metastases (CRLM) is increasing globally due to an interaction of environmental and genetic factors. A minority of patients with CRLM have surgically resectable disease, but for those who have resection as part of multimodal therapy [...] Read more.
The incidence of colorectal cancer and colorectal liver metastases (CRLM) is increasing globally due to an interaction of environmental and genetic factors. A minority of patients with CRLM have surgically resectable disease, but for those who have resection as part of multimodal therapy for their disease, long-term survival has been shown. Precision surgery—the idea of careful patient selection and targeting of surgical intervention, such that treatments shown to be proven to benefit on a population level are the optimal treatment for each individual patient—is the new paradigm of care. Key to this is the understanding of tumour molecular biology and clinically relevant mutations, such as KRAS, BRAF, and microsatellite instability (MSI), which can predict poorer overall outcomes and a poorer response to systemic therapy. The emergence of immunotherapy and hepatic artery infusion (HAI) pumps show potential to convert previously unresectable disease to resectable disease, in addition to established systemic and locoregional therapies, but the surgeon must be wary of poor-quality livers and the spectre of post-hepatectomy liver failure (PHLF). Volume modulation, a cornerstone of hepatic surgery for a generation, has been given a shot in the arm with the advent of liver venous depletion (LVD) ensuring significantly more hypertrophy of the future liver remnant (FLR). The optimal timing of liver resection for those patients with synchronous disease is yet to be truly established, but evidence would suggest that those patients requiring complex colorectal surgery and major liver resection are best served with a staged approach. In the operating room, parenchyma-preserving minimally invasive surgery (MIS) can dramatically reduce the surgical insult to the patient and lead to better perioperative outcomes, with quicker return to function. Full article
(This article belongs to the Special Issue Current Status, Challenges and Future of Precision Medicine for Colorectal Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop